Tirzepatide activates both GLP-1 and GIP receptors simultaneously, creating a more powerful appetite suppression and metabolic effect than semaglutide's single GLP-1 pathway
Exploratory endpoints reported included changes from baseline to week 104 in glycemic category, antihypertensive medication use, and lipid-lowering medication use
Zinman B, Aroda VR, Buse JB, Cariou B, Harris SB, Hoff ST, Pedersen KB, Tarp-Johansen MJ, Araki E, Investigators P
Furthermore, dual-action compounds engaging GLP-1 combined with glucose-dependent insulinotropic polypeptide (GIP) or glucagon pathways, alongside triple agonists incorporating all three receptors activation, have exhibited enhanced therapeutic potential
This could mean fewer injections over time, which many users may find more convenient